PersonExecutiveOperator
Richard Law
Richard Law is the Chief Business Officer of HAYA Therapeutics, the Lausanne- and San Diego-based biotech decoding the 'dark genome' to build RNA-guided medicines that reprogram disease-driving cell states. A computational chemist turned dealmaker with a Oxford PhD in molecular biophysics and an Imperial MBA, he spent over a decade at Evotec, then steered Exscientia through its 2021 Nasdaq IPO, marquee pharma partnerships, and 2024 merger with Recursion before joining HAYA in March 2025 to drive its partnering strategy and growth.
richard lawhaya therapeuticschief business officercboexscientiaevotec